Status:
COMPLETED
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Prostate Cancer
Eligibility:
MALE
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from di...
Detailed Description
OBJECTIVES: Primary * Assess prostate specific antigen response rate to docetaxel, doxorubicin hydrochloride, and prednisone in patients with hormone-refractory advanced prostate cancer. Secondary ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate with any of the following:
- Prostate-specific antigen ≥ 10 mg/dL
- Bone disease
- Bidimensional soft tissue disease
- Evaluable disease
- Advanced disease AND failed prior primary androgen ablation therapy, including anti-androgen withdrawal
- Disease not amenable to local curative treatment
- No known brain metastases
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Creatinine \< 2.0 mg/dL
- SGPT and SGOT \< 1.5 times upper limit of normal (ULN)
- Bilirubin ≤ ULN
- Hemoglobin ≥ 10 g/dL
- Ejection fraction ≥ 50%
- Peripheral neuropathy ≤ grade 1
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No previous history of or concurrent malignancy, except for any of the following:
- Inactive nonmelanoma skin cancer
- Disease-free for five or more years
- Adequately treated stage I or II cancer from which patient is currently in complete remission
- No other serious medical illness that would limit survival to less than 3 months
- No psychiatric condition that would prevent informed consent
- No active, uncontrolled bacterial, viral, or fungal infection
- No hemorrhagic disorder
- No history of severe hypersensitivity reaction to other drugs formulated with polysorbate 80
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No new hormonal treatment within the past 4 weeks
- No prior immunotherapy, chemotherapy, or bone-seeking radiopharmaceuticals (e.g., strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium)
- Prior bisphosphonates allowed
- At least 2 weeks since prior radiotherapy
- No other concurrent chemotherapy
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00416533
Start Date
August 1 2004
Last Update
January 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.